Immediate and Long-Term Outcomes of Drug Treatment in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
doi 10.18027/2224-5057-2018-8-3-68-77
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Russian Society of Clinical Oncology

Related search

Biology, Metastatic Patterns, and Treatment of Patients With Triple-Negative Breast Cancer

Clinical Cancer Reviews
2009English

Comparison of Long-Term Outcomes of Postmastectomy Radiotherapy Between Breast Cancer Patients With and Without Immediate Flap Reconstruction

PLoS ONE
Multidisciplinary
2016English

Phase II and Biomarker Study of Cabozantinib in Metastatic Triple‐Negative Breast Cancer Patients

Oncologist
Cancer ResearchMedicineOncology
2017English

Metastatic Triple Negative Breast Cancer: Optimizing Treatment Options, New and Emerging Targeted Therapies

Asia-Pacific Journal of Clinical Oncology
MedicineOncology
2017English

Severe and Prolonged Lymphopenia Observed in Patients Treated With Bendamustine and Erlotinib for Metastatic Triple Negative Breast Cancer

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2013English

Feasibility Study of Personalized Peptide Vaccination for Metastatic Recurrent Triple-Negative Breast Cancer Patients

Breast Cancer Research
Cancer ResearchOncology
2014English

Tumor Tissue microRNA Expression in Association With Triple-Negative Breast Cancer Outcomes

Breast Cancer Research and Treatment
Cancer ResearchOncology
2015English

Mesothelin Expression and Survival Outcomes in Triple Receptor Negative Breast Cancer

Clinical Breast Cancer
Cancer ResearchOncology
2013English

The Results of a Study of Chemotherapy With Bevacizumab, Oxaliplatin and Paclitaxel in Patients With Metastatic Triple Negative Breast Cancer

Malignant tumours
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy